FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2519-2529 December 9, 2004 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

Epithelial cancer of the ovary is a relatively uncommon gynecologic cancer in the United States, with approximately 25,580 new cases and 16,090 deaths anticipated in 2004.¹ Most patients present with advanced disease, which is managed with surgical resection followed by platinum-based chemotherapy. During the past decade, advances in chemotherapy have resulted in improved survival and in more effective treatment of relapsed disease. In addition, a better understanding of genetic risk factors has permitted a tailored approach to preventive strategies, such as bilateral salpingo-oophorectomy in selected women. This review describes the clinical features of epithelial ovarian cancer, with an emphasis on . . . [Full Text of this Article]

Epidemiology and Risk Factors

Familial Syndromes

Prophylactic Treatment for Women with Germ-Line Mutations in BRCA1 or BRCA2

Clinical Presentation

Surgery

Postoperative Chemotherapy

Early-Stage Disease

Advanced Disease

Management of Recurrent Disease

Prospects for a Brighter Future

Source Information

From the Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Boston.

Address reprint requests to Dr. Cannistra at the Program of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215, or at scannist@bidmc.harvard.edu.

Related Letters:

Cancer of the Ovary
Matulonis U., Abrahm J. L., Liu C.-M., Cannistra S. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:1268-1269, Mar 24, 2005. Correspondence

This article has been cited by other articles:

• Sehouli, J., Stengel, D., Oskay-Oezcelik, G., Zeimet, A. G., Sommer, H., Klare, P., Stauch, M., Paulenz, A., Camara, O., Keil, E., Lichtenegger, W. (2008). Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. JCO 26: 3176-3182 [Abstract] [Full Text]  
• Kikuchi, R., Tsuda, H., Kozaki, K.-i., Kanai, Y., Kasamatsu, T., Sengoku, K., Hirohashi, S., Inazawa, J., Imoto, I. (2008). Frequent Inactivation of a Putative Tumor Suppressor, Angiopoietin-Like Protein 2, in Ovarian Cancer. Cancer Res. 68: 5067-5075 [Abstract] [Full Text]  
• Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H-M., Nephew, K. P. (2008). Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. Cancer Res. 68: 4311-4320 [Abstract] [Full Text]  
• Banzato, A., Bobisse, S., Rondina, M., Renier, D., Bettella, F., Esposito, G., Quintieri, L., Melendez-Alafort, L., Mazzi, U., Zanovello, P., Rosato, A. (2008). A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity. Clin. Cancer Res. 14: 3598-3606 [Abstract] [Full Text]  
• Miller, K, Price, J H, Dobbs, S P, McClelland, R H, Kennedy, K, McCluggage, W G (2008). An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J. Clin. Pathol. 61: 652-657 [Abstract] [Full Text]  
• Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H. A., Peter, M. E., Ramakrishnan, V., Yamada, S. D., Lengyel, E. (2008). Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via {alpha}5-Integrin, which Is a Therapeutic Target. Cancer Res. 68: 2329-2339 [Abstract] [Full Text]  
• Schouten, L. J., Rivera, C., Hunter, D. J., Spiegelman, D., Adami, H.-O., Arslan, A., Beeson, W. L., van den Brandt, P. A., Buring, J. E., Folsom, A. R., Fraser, G. E., Freudenheim, J. L., Goldbohm, R. A., Hankinson, S. E., Lacey, J. V. Jr., Leitzmann, M., Lukanova, A., Marshall, J. R., Miller, A. B., Patel, A. V., Rodriguez, C., Rohan, T. E., Ross, J. A., Wolk, A., Zhang, S. M., Smith-Warner, S. A. (2008). Height, Body Mass Index, and Ovarian Cancer: A Pooled Analysis of 12 Cohort Studies. Cancer Epidemiol. Biomarkers Prev. 17: 902-912 [Abstract] [Full Text]  
• Marchini, S., Marabese, M., Marrazzo, E., Mariani, P., Cattaneo, D., Fossati, R., Compagnoni, A., Fruscio, R., Lissoni, A. A., Broggini, M. (2008). {Delta}Np63 expression is associated with poor survival in ovarian cancer. Ann Oncol 19: 501-507 [Abstract] [Full Text]  
• Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., Scudder, S., Morgan, R., Chen, H., Lenz, H.-J., Oza, A. M. (2008). Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. JCO 26: 76-82 [Abstract] [Full Text]  
• Fatouros, M., Baltoyiannis, G., Roukos, D. H. (2008). The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations. Ann. Surg. Oncol. 15: 21-33 [Abstract] [Full Text]  
• Bartel, F., Jung, J., Bohnke, A., Gradhand, E., Zeng, K., Thomssen, C., Hauptmann, S. (2008). Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival. Clin. Cancer Res. 14: 89-96 [Abstract] [Full Text]  
• Quinn, J. E., James, C. R., Stewart, G. E., Mulligan, J. M., White, P., Chang, G. K.F., Mullan, P. B., Johnston, P. G., Wilson, R. H., Harkin, D. P. (2007). BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy. Clin. Cancer Res. 13: 7413-7420 [Abstract] [Full Text]  
• Zheng, Y., Katsaros, D., Shan, S. J.C., de la Longrais, I. R., Porpiglia, M., Scorilas, A., Kim, N. W., Wolfert, R. L., Simon, I., Li, L., Feng, Z., Diamandis, E. P. (2007). A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. Clin. Cancer Res. 13: 6984-6992 [Abstract] [Full Text]  
• Smith, S., Su, D., Rigault de la Longrais, I. A., Schwartz, P., Puopolo, M., Rutherford, T. J., Mor, G., Yu, H., Katsaros, D. (2007). ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy. JCO 25: 5172-5179 [Abstract] [Full Text]  
• Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., McGuire, W. (2007). Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer. JCO 25: 5180-5186 [Abstract] [Full Text]  
• Kim, T. J., Ravoori, M., Landen, C. N., Kamat, A. A., Han, L. Y., Lu, C., Lin, Y. G., Merritt, W. M., Jennings, N., Spannuth, W. A., Langley, R., Gershenson, D. M., Coleman, R. L., Kundra, V., Sood, A. K. (2007). Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma. Cancer Res. 67: 9337-9345 [Abstract] [Full Text]  
• Iorio, M. V., Visone, R., Di Leva, G., Donati, V., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.-G., Alder, H., Calin, G. A., Menard, S., Croce, C. M. (2007). MicroRNA Signatures in Human Ovarian Cancer. Cancer Res. 67: 8699-8707 [Abstract] [Full Text]  
• Spentzos, D., Cannistra, S. A, Grall, F., Levine, D. A, Pillay, K., Libermann, T. A, Mantzoros, C. S (2007). IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer 14: 781-790 [Abstract] [Full Text]  
• Callahan, M. J., Crum, C. P., Medeiros, F., Kindelberger, D. W., Elvin, J. A., Garber, J. E., Feltmate, C. M., Berkowitz, R. S., Muto, M. G. (2007). Primary Fallopian Tube Malignancies in BRCA-Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. JCO 25: 3985-3990 [Abstract] [Full Text]  
• Wei, S., Kryczek, I., Edwards, R. P., Zou, L., Szeliga, W., Banerjee, M., Cost, M., Cheng, P., Chang, A., Redman, B., Herberman, R. B., Zou, W. (2007). Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Res. 67: 7487-7494 [Abstract] [Full Text]  
• McIntosh, M. W., Liu, Y., Drescher, C., Urban, N., Diamandis, E. P. (2007). Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma. Clin. Cancer Res. 13: 4422-4428 [Abstract] [Full Text]  
• Fehrmann, R. S. N., Li, X.-y., van der Zee, A. G. J., de Jong, S., te Meerman, G. J., de Vries, E. G. E., Crijns, A. P. G. (2007). Profiling Studies in Ovarian Cancer: A Review. The Oncologist 12: 960-966 [Abstract] [Full Text]  
• Lassmann, S., Shen, Y., Jutting, U., Wiehle, P., Walch, A., Gitsch, G., Hasenburg, A., Werner, M. (2007). Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy. Clin. Cancer Res. 13: 4083-4091 [Abstract] [Full Text]  
• Burger, R. A. (2007). Experience With Bevacizumab in the Management of Epithelial Ovarian Cancer. JCO 25: 2902-2908 [Abstract] [Full Text]  
• Darcy, K. M., Tian, C., Reed, E. (2007). A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy. Cancer Res. 67: 4474-4481 [Abstract] [Full Text]  
• Lambeck, A. J.A., Crijns, A. P.G., Leffers, N., Sluiter, W. J., ten Hoor, K. A., Braid, M., van der Zee, A. G.J., Daemen, T., Nijman, H. W., Kast, W. M. (2007). Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7. Clin. Cancer Res. 13: 2385-2391 [Abstract] [Full Text]  
• Cannistra, S. A. (2007). Gynecologic Oncology or Medical Oncology: What's in a Name?. JCO 25: 1157-1159 [Full Text]  
• Saucier, J. M., Yu, J., Gaikwad, A., Coleman, R. L., Wolf, J. K., Smith, J. A. (2007). Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model. J Oncol Pharm Pract 13: 39-45 [Abstract]  
• Sawada, K., Radjabi, A. R., Shinomiya, N., Kistner, E., Kenny, H., Becker, A. R., Turkyilmaz, M. A., Salgia, R., Yamada, S. D., Vande Woude, G. F., Tretiakova, M. S., Lengyel, E. (2007). c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion. Cancer Res. 67: 1670-1679 [Abstract] [Full Text]  
• DelloRusso, C., Welcsh, P. L., Wang, W., Garcia, R. L., King, M.-C., Swisher, E. M. (2007). Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation. Mol Cancer Res 5: 35-45 [Abstract] [Full Text]  
• Surowiak, P., Materna, V., Kaplenko, I., Spaczynski, M., Dolinska-Krajewska, B., Gebarowska, E., Dietel, M., Zabel, M., Lage, H. (2006). ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome. Clin. Cancer Res. 12: 7149-7158 [Abstract] [Full Text]  
• Kyrgiou, M., Salanti, G., Pavlidis, N., Paraskevaidis, E., Ioannidis, J. P. A. (2006). Survival Benefits With Diverse Chemotherapy Regimens for Ovarian Cancer: Meta-analysis of Multiple Treatments.. JNCI J Natl Cancer Inst 98: 1655-1663 [Abstract] [Full Text]  
• Beehler, G. P., Sekhon, M., Baker, J. A., Teter, B. E., McCann, S. E., Rodabaugh, K. J., Moysich, K. B. (2006). Risk of Ovarian Cancer Associated with BMI Varies by Menopausal Status. J. Nutr. 136: 2881-2886 [Abstract] [Full Text]  
• Pastorino, F., Brignole, C., Di Paolo, D., Nico, B., Pezzolo, A., Marimpietri, D., Pagnan, G., Piccardi, F., Cilli, M., Longhi, R., Ribatti, D., Corti, A., Allen, T. M., Ponzoni, M. (2006). Targeting Liposomal Chemotherapy via Both Tumor Cell-Specific and Tumor Vasculature-Specific Ligands Potentiates Therapeutic Efficacy.. Cancer Res. 66: 10073-10082 [Abstract] [Full Text]  
• Colombo, N., Formelli, F., Cantu, M. G., Parma, G., Gasco, M., Argusti, A., Santinelli, A., Montironi, R., Cavadini, E., Baglietto, L., Guerrieri-Gonzaga, A., Viale, G., Decensi, A. (2006). A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer.. Cancer Epidemiol. Biomarkers Prev. 15: 1914-1919 [Abstract] [Full Text]  
• Moore, L. E., Fung, E. T., McGuire, M., Rabkin, C. C., Molinaro, A., Wang, Z., Zhang, F., Wang, J., Yip, C., Meng, X.-Y., Pfeiffer, R. M. (2006). Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.. Cancer Epidemiol. Biomarkers Prev. 15: 1641-1646 [Abstract] [Full Text]  
• Rocconi, R. P., Straughn, J. M. Jr., Leath, C. A. III, Kilgore, L. C., Huh, W. K., Barnes, M. N. III, Partridge, E. E., Alvarez, R. D. (2006). Pegylated liposomal Doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.. The Oncologist 11: 336-341 [Abstract] [Full Text]  
• Borgono, C. A., Kishi, T., Scorilas, A., Harbeck, N., Dorn, J., Schmalfeldt, B., Schmitt, M., Diamandis, E. P. (2006). Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer. Clin. Cancer Res. 12: 1487-1493 [Abstract] [Full Text]  
• Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., Burger, R. A., the Gynecologic Oncology Group, (2006). Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. NEJM 354: 34-43 [Abstract] [Full Text]  
• Cannistra, S. A. (2006). Intraperitoneal Chemotherapy Comes of Age. NEJM 354: 77-79 [Full Text]  
• Horak, P., Pils, D., Kaider, A., Pinter, A., Elandt, K., Sax, C., Zielinski, C. C., Horvat, R., Zeillinger, R., Reinthaller, A., Krainer, M. (2005). Perturbation of the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cascade in Ovarian Cancer: Overexpression of FLIPL and Deregulation of the Functional Receptors DR4 and DR5. Clin. Cancer Res. 11: 8585-8591 [Abstract] [Full Text]  
• Shiftan, L., Israely, T., Cohen, M., Frydman, V., Dafni, H., Stern, R., Neeman, M. (2005). Magnetic Resonance Imaging Visualization of Hyaluronidase in Ovarian Carcinoma. Cancer Res. 65: 10316-10323 [Abstract] [Full Text]  
• Spentzos, D., Levine, D. A., Kolia, S., Otu, H., Boyd, J., Libermann, T. A., Cannistra, S. A. (2005). Unique Gene Expression Profile Based on Pathologic Response in Epithelial Ovarian Cancer. JCO 23: 7911-7918 [Abstract] [Full Text]  
• Avril, N., Sassen, S., Schmalfeldt, B., Naehrig, J., Rutke, S., Weber, W. A., Werner, M., Graeff, H., Schwaiger, M., Kuhn, W. (2005). Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer. JCO 23: 7445-7453 [Abstract] [Full Text]  
• Downie, D., McFadyen, M. C.E., Rooney, P. H., Cruickshank, M. E., Parkin, D. E., Miller, I. D., Telfer, C., Melvin, W. T., Murray, G. I. (2005). Profiling Cytochrome P450 Expression in Ovarian Cancer: Identification of Prognostic Markers. Clin. Cancer Res. 11: 7369-7375 [Abstract] [Full Text]  
• Matulonis, U., Abrahm, J. L., Liu, C.-M., Cannistra, S. A. (2005). Cancer of the Ovary. NEJM 352: 1268-1269 [Full Text]  
• Price, F. V., Penson, R. T., Sahani, D., Bell, D. A. (2005). Case 37-2004: Postmenopausal Bleeding and a Cystic Ovarian Mass. NEJM 352: 1269-1270 [Full Text]